PRA is proud to join forces with a group of highly skilled and experienced patient advocates — collectively working towards improving the way patients with rare diseases are integrated into the clinical development lifecycle.
About the Committee
The Rare Diseases Advisory Committee (RDAC) is an independent and autonomous volunteer group that advises and works with PRA’s Center for Rare Diseases. Together they work to better understand the ways in which clinical trials can be revolutionized to be more effective and accessible for these patients and their unique challenges.
The inaugural committee members are a group comprised of experienced and talented individuals, all with a deep connection to the rare diseases community.
About the Collaboration
Working alongside the RDAC is the international team of experts at PRA’s Center for Rare Diseases. This team has dedicated itself to groundbreaking research and the development of life-changing therapies — specifically for patients with rare diseases. Since 2012, the Center has served more than 50,000 patients in over 300 clinical studies, leading to 18 approved drugs that fight rare diseases.
Improving Treatment for Rare Cancers
In recognition of World Cancer Day on February 4th, we explore questions around the latest rare cancer research, treatments, and how to improve…
Rare Disease Newsletter
This quarterly publication will keep you informed about key news in the world of rare disease clinical research and update you on what the PRA Health…
Studying Rare Diseases Helps Advance Common Disease Treatment
Many rare diseases have unexpected connections with common diseases. These relationships can lead us to treatments not only for these rare diseases,…